Hershey Q1 Easter Sell-Through Exceeds Estimates; GLP-1 Lift Drives Mint, Gum Sales
Hershey’s Q1 Easter sell-through beat estimates, with Reese’s up 11% and Hershey’s up 10%, and premium chocolate innovations planned for H2. CEO Kirk Tanner said GLP-1 drugs are boosting mint and gum sales including Ice Breakers, though Q2 organic sales may dip due to timing shifts.
1. Strong Q1 Performance
Hershey delivered robust Q1 results as Easter sell-through exceeded expectations despite a shorter season, with non-seasonal core brands Reese’s and Hershey’s rising 11% and 10%, respectively. The premium chocolate segment also showed growth, and the company plans to accelerate innovation with tent-pole events and new product launches in the second half.
2. Q2 Outlook and Timing Impacts
Management anticipates a slight decline in Q2 organic sales due to timing shifts from earlier spring program shipments and international order pull-forwards. Snacks segment growth lagged consumption levels, affected by private label competition and prior product recalls, but no structural changes are expected in the full-year outlook.
3. GLP-1 Tailwind in Mints and Gum
CEO Kirk Tanner highlighted that rising use of GLP-1 weight-loss drugs is lifting demand for mints and chewing gum, with Ice Breakers seeing notable sales gains. This trend offers a fresh growth driver outside traditional confectionery categories.
4. Market Share and Macroeconomic Factors
North America confectionery market share edged lower due to increased competitor innovation and merchandising. Management noted favorable consumer elasticities despite geopolitical uncertainties and higher gas prices.